- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04167319
A Feasibility Study Investigating Chemotherapy-induced Neuropathy Using Multi-frequency Tactilometry and Patient-reported Outcomes (PRO) (CINCAN-1)
Chemotherapy induced peripheral neuropathy (CIPN) is among the most feared side effects to cancer treatment. The development of CIPN can lead to discontinuation or omission of antineoplastic drugs, possibly affecting efficacy of cancer treatment. There is a lack of knowledge about the natural course of CIPN and to this date, there are no available methods for the early detection of CIPN. With no effective prevention or treatment options, the condition has severe impact on patient quality of life and healthcare expenditure.
This study will investigate the natural course of paclitaxel- and oxaliplatin induced peripheral neuropathy using novel diagnostic techniques. Multi-frequency vibrational technology has provided an objective method for the early detection of diabetic neuropathy. Our study will test the feasibility of this method within the field of clinical oncology and CIPN.
연구 개요
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Roskilde, 덴마크, 4000
- Department of Clinical Oncology and Palliative Care
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- ≥ 18 years of age
- A diagnosis of cancer.
- Fulfil the criteria for starting chemotherapy.
- Scheduled to undergo at least 4 courses of paclitaxel- or oxaliplatin-based chemotherapy.
- No prior paclitaxel, oxaliplatin or other neurotoxic chemotherapy.
Exclusion Criteria:
- Unable to complete PRO measures.
- Previous neurotoxic chemotherapy.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
---|---|
Paclitaxel
Patients scheduled to receive paclitaxel as part of their standard treatment
|
We will observe the natural course of CIPN using multiple measurements
|
Oxaliplatin
Patients scheduled to receive oxaliplatin as part of their standard treatment
|
We will observe the natural course of CIPN using multiple measurements
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Difference in VPT from baseline to 6 mo.
기간: through study completion, an average of 1 year and 6 months
|
For patients receiving paclitaxel: Difference in vibrograms from baseline compared to vibrograms after the end of the 6th course of chemotherapy or the last course of chemotherapy (if before course no. 6).
|
through study completion, an average of 1 year and 6 months
|
Difference in VPT from Baseline to 4 mo.
기간: through study completion, an average of 1 year and 6 months
|
For patients receiving oxaliplatin: Difference in vibrograms from baseline compared to vibrograms after the end of the 4th course of chemotherapy or the last course of chemotherapy (if before course no.
4).
|
through study completion, an average of 1 year and 6 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Difference in PRO from baseline and during 1. course chemotherapy.
기간: up to 5 days
|
Difference in the NCCTG-CIPN Questionnaire from baseline compared to 4 days after initiation of chemotherapy course no. 1.
|
up to 5 days
|
Difference in VPT from baseline and during 1. course chemotherapy
기간: up to 5 days
|
Difference in the Vibrograms from baseline compared to 4 days after initiation of chemotherapy course no. 1.
|
up to 5 days
|
Difference in PRO from baseline to after chemotherapy course no. 3
기간: through study completion, an average of 1 year and 6 months
|
For patients receiving paclitaxel: Difference in EORTC-QLQ-CIPN20 from baseline compared to after chemotherapy course no. 3.
|
through study completion, an average of 1 year and 6 months
|
Difference in PRO from baseline to after chemotherapy course no. 2
기간: through study completion, an average of 1 year and 6 months
|
For patients receiving oxaliplatin: Difference in EORTC-QLQ-CIPN20 from baseline compared to after chemotherapy course no. 2. Some patients receiving oxaliplatin will have 6 courses of planned chemotherapy or planned metastatic treatment, in this case comparison will be made after chemotherapy course no. 3.
|
through study completion, an average of 1 year and 6 months
|
Difference in VPT from baseline to af chemotherapy course no. 3
기간: through study completion, an average of 1 year and 6 months
|
For patients receiving paclitaxel: Difference in the Vibrograms from baseline compared to after chemotherapy course no. 3.
|
through study completion, an average of 1 year and 6 months
|
Difference in VPT from baseline to af chemotherapy course no. 2
기간: through study completion, an average of 1 year and 6 months
|
For patients receiving oxaliplatin: Difference in the Vibrograms from baseline compared to after chemotherapy course no. 2. Some patients receiving oxaliplatin will have 6 courses of planned chemotherapy or planned metastatic treatment, in this case comparison will be made after chemotherapy course no. 3.
|
through study completion, an average of 1 year and 6 months
|
No. of discontinuations
기간: through study completion, an average of 1 year and 6 months
|
Number of patients not completing their planned courses of chemotherapy (reasons for discontinuation will be registered).
|
through study completion, an average of 1 year and 6 months
|
No. of dose reductions
기간: through study completion, an average of 1 year and 6 months
|
Number of patients that need reductions of chemotherapy dose (reasons will be registered)
|
through study completion, an average of 1 year and 6 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- REG-088-2019
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .